Since our inception, RemeGen has been dedicated to the research and development of biologics with novel targets, innovative design and breakthrough potential with the mission of fulfilling global unmet clinical needs for patients worldwide. We have established fully integrated, end-to-end R&D platforms covering all key functions of biologics development including discovery, pre-clinical pharmacology, process and quality development, clinical development, and manufacturing in compliance with global good manufacturing practices (GMP).
RemeGen’s robust pipeline of innovative biologics was made possible by our world-class proprietary research and development engine consisting of three specialized platforms: antibody and fusion protein platform, antibody-drug conjugate (ADC) platform and bifunctional antibody (HiBody) platform. Our technology platforms enable the discovery, screening and development of new molecules and proprietary technologies, and the efficient optimization of manufacturing processes in order to ensure end-to-end integration of drugs in the pipeline from R&D to commercialization.
We are constituting a professional excellent talent team composed of more than one thousand people.
Dr. Jianmin Fang possesses rich R&D experience on developing innovative biological drugs in famous research institutions and biopharmaceutical companies. Led by Dr. Fang, RemeGen has established a strong research and development team, covering all major functions involved in the development of biologic drugs.
Under the leadership of Dr. Ruyi He, our Chief Medical Officer, RemeGen has built a development team responsible for executing our global clinical development plan while adhering to rigorous trial design and trial operational excellence.
In the spirit of following where the data leads, our clinical development team often discovers and explores unanticipated clinical opportunities, which in turn spur the organic growth and expansion of our clinical program and pipeline.
